JP2022529208A5 - - Google Patents

Info

Publication number
JP2022529208A5
JP2022529208A5 JP2021556884A JP2021556884A JP2022529208A5 JP 2022529208 A5 JP2022529208 A5 JP 2022529208A5 JP 2021556884 A JP2021556884 A JP 2021556884A JP 2021556884 A JP2021556884 A JP 2021556884A JP 2022529208 A5 JP2022529208 A5 JP 2022529208A5
Authority
JP
Japan
Prior art keywords
approximately
pharmaceutical composition
composition according
dose
metformin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021556884A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022529208A (ja
JP7586830B2 (ja
Filing date
Publication date
Priority claimed from US16/364,063 external-priority patent/US11033544B2/en
Application filed filed Critical
Publication of JP2022529208A publication Critical patent/JP2022529208A/ja
Publication of JP2022529208A5 publication Critical patent/JP2022529208A5/ja
Application granted granted Critical
Publication of JP7586830B2 publication Critical patent/JP7586830B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021556884A 2019-03-25 2020-03-25 低用量の三重複合製剤 Active JP7586830B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16/364,063 US11033544B2 (en) 2019-03-25 2019-03-25 Low-dose triple combination formulation
US16/364,063 2019-03-25
PCT/IB2020/000214 WO2020194052A1 (en) 2019-03-25 2020-03-25 Low-dose triple combination formulation

Publications (3)

Publication Number Publication Date
JP2022529208A JP2022529208A (ja) 2022-06-20
JP2022529208A5 true JP2022529208A5 (enExample) 2023-04-05
JP7586830B2 JP7586830B2 (ja) 2024-11-19

Family

ID=72606637

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021556884A Active JP7586830B2 (ja) 2019-03-25 2020-03-25 低用量の三重複合製剤

Country Status (11)

Country Link
US (5) US11033544B2 (enExample)
EP (1) EP3946344A4 (enExample)
JP (1) JP7586830B2 (enExample)
KR (1) KR20220004027A (enExample)
CN (2) CN113924096A (enExample)
AU (2) AU2020247542A1 (enExample)
BR (1) BR112021018994A2 (enExample)
CA (1) CA3134800A1 (enExample)
MX (2) MX2021011746A (enExample)
TW (2) TW202102209A (enExample)
WO (1) WO2020194052A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11033544B2 (en) * 2019-03-25 2021-06-15 The George Institute for Global Health Low-dose triple combination formulation
KR102853692B1 (ko) * 2021-07-08 2025-09-02 한미약품 주식회사 시타글립틴, 다파글리플로진 및 메트포르민을 포함하는 경구용 복합정제
EP4415723A4 (en) * 2021-10-12 2025-09-03 Unison Pharmaceuticals Pvt Ltd PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF SITAGLIPTIN AND EMPAGLIFLOZIN
TR2023001202A1 (tr) * 2023-02-02 2024-08-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Fi̇lm kapli empagliflozin ve metformin hi̇droklorür tabletleri̇
KR20260000968A (ko) * 2024-06-26 2026-01-05 주식회사 종근당 제2형 당뇨병 치료용 조성물, 조합물 및 병용 요법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200904405A (en) * 2007-03-22 2009-02-01 Bristol Myers Squibb Co Pharmaceutical formulations containing an SGLT2 inhibitor
JP5685550B2 (ja) * 2009-02-13 2015-03-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｇｌｔ２阻害剤、ｄｐｐ−ｉｖ阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用
US20170135981A1 (en) 2014-05-16 2017-05-18 Astrazeneca Ab Method for Suppressing Glucagon Secretion of an SGLT2 Inhibitor
WO2016040462A2 (en) * 2014-09-09 2016-03-17 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
US11033544B2 (en) * 2019-03-25 2021-06-15 The George Institute for Global Health Low-dose triple combination formulation

Similar Documents

Publication Publication Date Title
JP2022529208A5 (enExample)
EP4125896B1 (en) Treatment of type 2 diabetes with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl} piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof
IL274943B1 (en) Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases
JP2022529312A5 (enExample)
EP2419097B1 (en) Pharmaceutical composition comprising (1s)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-d-glucitol and metformin and uses thereof in the treatment of diabetes
JP6358515B2 (ja) Ｓｇｌｔ２阻害薬と抗高血圧薬との組み合わせ
TW202545526A (zh) 低劑量三重組合調配物
US20230346817A1 (en) Composition and use of sglt-2 inhibitor and angiotensin receptor blockers
TWI606848B (zh) 包含格米列汀與美氟明的組合藥物及其製備方法
US20240366579A1 (en) Pharmaceutical composition comprising gpr40 agonist and sglt-2 inhibitor
JP2020536121A5 (enExample)
US10278943B2 (en) Method of treating hyperglycemia
JP2024505143A5 (enExample)
Davis Oral hypoglycaemic drugs for the treatment of type 2 diabetes mellitus
CN110753540A (zh) 瑞格列净的口服药物制剂
WO2019162800A1 (en) Pharmacutical composition comprising remogliflozin and antidiabetic agent
CN116157132A (zh) 一种降低血糖的组合、应用和方法
CN115192625A (zh) 一种口服组合物
RU2021130019A (ru) Состав низкодозовой тройной комбинации
RU2021130142A (ru) Низкодозовый тройной комбинированный состав
HK40097553A (zh) 包括gpr40促进剂以及sglt-2抑制物的医药组成物
NZ747331B2 (en) Combinations of linagliptin and metformin
EA022732B1 (ru) Фармацевтическая композиция и набор для профилактики и лечения нарушений, связанных с избыточным весом или ожирением, их применение и способ профилактики и лечения нарушений, связанных с избыточным весом или ожирением
RU2006110358A (ru) Способ лечения нарушений метаболизма, прежде всего диабета или заболеваний или состояний, связанных с диабетом